There is one clinical trial.
The authors hypothesize that the SARS-CoV-2 virus can affect the kidneys, causing them to be damaged. The present study aims to explain the mechanisms of kidney injury in patients diagnosed with COVID-19.
Description: estimated glomerular filtration rate (eGFR), ml/min, in groups with mild, moderate and severe COVID-19Measure: The effect of COVID-19 severity on the severity of renal failure Time: 2 months
Description: viral RNA concentration in urine, ME/mlMeasure: The expression of viral RNA in the urine with the severity of renal failure Time: 2 months
Description: albumine excretion with urine, g/mlMeasure: The severity of microalbuminuria in patients with COVID-19 of different conditions and renal failure Time: 2 months
Description: estimated glomerular filtration rate (eGFR), ml/minMeasure: Assessment of the severity of renal impairment in patients who died from COVID-19 Time: 2 months
Description: Duration of viral RNA detection in urine by PCR, weeksMeasure: Estimation of the duration of urinary viral RNA isolation in patients undergoing COVID-19 Time: 2 months
Description: expression of ACE-2 by imminohistochemistry at autopsy specimenMeasure: Expression of ACE-2 receptors in the kidneys of patients with renal failure who died from COVID-19 Time: 2 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports